What Is Mounjaro? FDA Approval, Licensing in Türkiye, Price, and Reimbursement Status

What Is Mounjaro (Tirzepatide)? — Introduction and Why It Matters

Mounjaro®, whose active ingredient is tirzepatide, is the first ‘dual incretin agonist’: a single molecule simultaneously stimulating two different gut hormone receptors (GLP-1 and GIP). Developed to treat type 2 diabetes (T2D), it is also used under the Zepbound® brand for obesity/weight management. The drug is developed and manufactured by the American pharmaceutical company Eli Lilly and Company (Lilly).

Although commonly called a ‘weight-loss injection,’ tirzepatide does more than suppress appetite: it lowers glucose, increases glucose-dependent insulin secretion, suppresses glucagon, and slows gastric emptying to prolong satiety. These combined actions can substantially reduce HbA1c and produce weight loss reaching double-digit percentages in clinical trials.

Who May Be Considered?

• People with T2D: Those with elevated HbA1c and/or excess weight
• Obesity/weight management: Those meeting appropriate BMI and clinical criteria, with or without diabetes
• Expectations: Reduced appetite, fullness with smaller portions, gradual weight loss

Note: Medical assessment is essential; use may be inappropriate with certain conditions or medications.

Why Does It Matter?

• New class: The first dual incretin agonist (GLP-1 + GIP).
• Strong efficacy: Reduces HbA1c by ~2% and produces up to 15-20% weight loss.
• Dual benefit: Targets diabetes and obesity simultaneously.
• Preventive effect: Reduced T2D risk by 94% in people with prediabetes.
• Convenient use: 1 injection weekly.
• Cardiometabolic data: SURPASS-CVOT demonstrated non-inferiority for cardiovascular events (not superiority—see the update box above).

Mechanism of Action

1) GLP-1R agonism

Increases glucose-dependent insulin secretion, suppresses glucagon, slows gastric emptying, and reduces appetite.

2) GIP-R agonism

Improves β-cell function and insulin sensitivity, adding synergy to GLP-1 effects.

3) Prolonged action

A C20 fatty-acid side chain increases albumin binding → t½ ≈ 5 days → supports weekly dosing.

FDA Approval Process – Timeline

• May 13, 2022: Mounjaro® (tirzepatide) — FDA approval for type 2 diabetes.
• November 8, 2023: Zepbound® — FDA approval for chronic weight management (obesity/overweight).
• December 20, 2024: Zepbound® — Additional indication approved for obstructive sleep apnea (OSA) associated with obesity.
• February 23, 2026: Approval of a 4-dose, single-patient monthly KwikPen option for Zepbound® (a device/presentation update rather than a new treatment indication).

What Are Mounjaro’s Price, Licensing, and Reimbursement Status?

Prices in Türkiye (as of August 2026)

Note: Reference drug prices in Türkiye may change periodically (depending on exchange-rate/pricing decisions). The 2.5 mg and 15 mg prices have been verified against official reference sources; the 10 mg price was found to have decreased slightly in August 2026 (by approximately 300 TL). We recommend consulting your pharmacist for the current exact price.

Licensing in Türkiye

4.1 Therapeutic Indications

Type 2 Diabetes Mellitus:

• As an adjunct to diet and exercise in adults with uncontrolled type 2 DM.
• As monotherapy when metformin cannot be used.
• In combination with other antidiabetic drugs (except DPP-4 inhibitors and other GLP-1 analogues).

Body Weight Management:

• As an adjunct to a reduced-calorie diet + increased physical activity,
• In adults with BMI ≥30 kg/m² (obesity),
• In those with BMI ≥27-<30 kg/m² and a comorbidity such as hypertension, dyslipidemia, sleep apnea, CVD, prediabetes, or type 2 DM.

Reimbursement Status

• SGK does not cover it in Türkiye—for either diabetes or obesity.
• It can be purchased from pharmacies.

This information is for general education and does not replace a doctor/pharmacist. Consult your pharmacist for current prices.

Dosing Schedule and How to Use It

• Injection sites: Abdomen, thigh, upper arm (rotate sites).
• Keep the same weekly day: When changing the day, allow ≥72 hours between doses.
• Missed dose: Administer within 96 hours (4 days); if >4 days, skip it and resume the scheduled day.
• Do not mix with insulin: Do not mix in the same syringe; inject at a different site.

Absorption, Distribution, Metabolism, and Elimination (ADME)

Drug Interactions

• Oral contraceptives: Slower gastric emptying may reduce exposure. An additional barrier method or nonoral contraception is recommended for 4 weeks after initiation and after each dose increase.
• Insulin / sulfonylureas: Increased hypoglycemia risk ↑ → the concomitant dose may be reduced.
• CYP interactions: Not expected (peptide structure).
• Oral drugs with a narrow therapeutic range: Absorption may be affected; close clinical monitoring is recommended.

Side-Effect Profile

Common: Nausea, vomiting, diarrhea/constipation, reduced appetite, abdominal pain; headache, fatigue; injection-site reactions.

Less Common: Risk of acute kidney injury with dehydration (particularly with severe GI symptoms); gallbladder events (cholelithiasis/cholecystitis).

Serious / Rare: Acute pancreatitis; hypersensitivity reactions; class warning for thyroid C-cell tumors.

Tolerability: Gradual titration and administration after meals may help reduce GI adverse effects.

Precautions

• Contraindicated: Personal/family history of medullary thyroid carcinoma (MTC) or MEN-2; severe hypersensitivity.
• Pancreatitis: Severe, persistent abdominal pain/increased amylase–lipase ↑ → stop the drug and assess.
• Gallbladder: Imaging and clinical assessment for relevant symptoms.
• GI symptoms & fluids: Maintain adequate hydration in the first weeks; watch for AKI risk.
• Diabetic retinopathy: Rapid glycemic improvement may temporarily worsen it; arrange eye monitoring.
• Pregnancy/breastfeeding: Limited human data; decide based on risks and benefits.
• Concomitant treatments: Review insulin/sulfonylurea doses; apply the 4-week rule for oral contraceptives.

Mounjaro (tirzepatide) is the first dual incretin agonist, a breakthrough in metabolic disease treatment that simultaneously targets diabetes and obesity, providing substantial weight loss and glycemic control. It must be used under medical supervision.